Tumor Mutational Burden Assessed By A Targeted Ngs Assay To Predict Clinical Benefit From Immune Checkpoint Inhibitors In Non-Small Cell Lung Cancer.

Sacha Rothschild,Ilaria Alborelli,Katharina Leonards,Laura P Leuenberger,Spasenija Savic Prince,Kirsten D Mertz, Severin Poechtrager,Alfred Zippelius,Heinz Philipp Laubli, Jasmin Haegele,Markus Tolnay,Lukas Bubendorf,Luca Quagliata,Philip Jermann

JOURNAL OF CLINICAL ONCOLOGY（2019）

引用 1|浏览4

暂无评分

摘要

e14266Background: In non-small cell lung cancer (NSCLC) immune checkpoint inhibitors (ICIs) significantly improve overall survival (OS). Tumor mutational burden (TMB) has emerged as a predictive bi...

查看译文

关键词

Lung cancer,Cancer research,Medicine,Immune checkpoint inhibitors,Non small cell,Overall survival,Targeted ngs

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要